Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Do Negative Trials Count More Than Successful Ones?

Related Content

Is Fabre-Kramer’s Gepirone Antidepressant Rising From The Dead After 8 Years?

Sep 08 2015

Third Strike For Gepirone ER: Fabre-Kramer/GSK Antidepressant “Not Approvable” Again

Nov 05 2007

Related Companies

Fabre-Kramer Pharmaceuticals

Bristol Myers Squibb Company

Merck & Co., Inc.

Additional Topics

United States Advisory Committees BioPharmaceutical

More from United States

More from North America

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window